Regorafenib Combined With Fulvestrant in Recurrent Low-Grade Serous Ovarian Cancer

NCT05113368 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

31

Enrollment

OTHER

Sponsor class

Conditions

Ovarian Cancer
Serous Ovarian Cancer

Interventions

DRUG: Regorafenib
DRUG: Fulvestrant

Sponsor

Sarah K. Lynam MD

Collaborators

[object Object]